TP方案治疗晚期非小细胞肺癌的临床观察

TP Project Cure the Afeernoon Uncellule Lung Cancer's Clinic Be Observed

目的：评价TP方案冶疗晚期非小细胞肺癌的疗效和毒副反应。方法：TP方案：紫杉醇（Paclitaxel PTX）150mg／m^2，静脉点滴，第1天。持续3h，顺铂（Cisplatin PDD）20mg／m^2，静脉点滴，第1天一第5天，21d为1周期。2周期-3周期为1个疗程。结果：TP方案29例，完全缓解（CR）1例（3．4％），部分缓解（PR）12例（41．4％），稳定（SD）11例（37．9％），进展（PD）5例（17．2％），总有效率44．8％。TP方案剂量限制性毒性主要为脱发、周围神经毒性、关节肌肉疼痛、白细胞下降发生率分别为93．1％、72．4％和51．7％，无Ⅳ度反应．患者均能够较好地耐受，不影响化疗继续进行。结论：TP方案冶疗晚期非小细胞肺癌疗效较好，毒性可耐受，有利于提高患者的生命质量延长生存期。

Objective To evaluate the curative and side＇effects of paclitaxel（PTX） and cisplatin（PDD） regimen for treating advanced non-small cell lung cancer（NSCLC）. Methods From January 2000 to December 2004, a total of 29 patients with abvanced NSCLCreceived paclitaxel 150 mg/m^2 by 3-hour infusion on day 1 and cisplatin 20 mg/m^2 on days 1-5 of 21-day cycle. Curative and side effects were evaluated after two to three cycles were completed. Results A total of 29 patients were enrolled. The overall respose rate was 44.8 % （3.4% CR,41.4% PR, 37.9 % C D, and 17.2% PD）. The main side effects were alopecia. Peripheral neurotoxicity/myalgia and leucopenia, but they were acceptable. No WHO grade Ⅳ toxicity occurred. Conclusion The corrloined recjrnen of PTX and PDD for treating advanced NSCLC has a high response rate and tderable side effects.